PMPraveenkumar Murugavelu

Praveenkumar Murugavelu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Praveenkumar Murugavelu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Alona Kuzmina

    The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel

    1 shared publication
  • Ferdinand Heyn

    Department of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

    1 shared publication
  • Heli Glebko

    The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel

    1 shared publication
  • Ina Ambiel

    Department of Infectious Diseases, Integrative Virology, CIID, Heidelberg University, Medical Faculty Heidelberg, Heidelberg, Germany

    1 shared publication
  • Jagrity Rani

    The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel

    1 shared publication
  • Liron Levin

    Bioinformatics Core Facility, llse Katz Institute for Nanoscale Science and Technology, Ben-Gurion University of the Negev, Beer-Sheva, Israel

    1 shared publication

Latest Publications

  • Open Access

    Inhibition of CDK12/CDK13-CYCLIN K rewires P-TEFb signaling to reverse HIV-1 latency and modulate cellular gene expression

    by Praveenkumar Murugavelu, Jagrity Rani, Heli Glebko, Ina Ambiel, Nadine Tibroni, Nili Tickotsky, Ferdinand Heyn, Philipp Schommers, Liron Levin, Alona Kuzmina, et al.

    Persistent HIV-1 latency in long-lived CD4⁺ T-cell reservoirs remains a major obstacle towards viral eradication. Current antiretroviral therapy (cART) exhibits limited clinical efficacy, highlighting the need for new therapeutic interventions. Here, we identify the CDK12/CDK13-Cyclin K (CCNK) complex as a regulator of HIV-1 latency. Pharmacological inhibition of CDK12/CDK13-CCNK with the SR-4835 inhibitor robustly reversed HIV-1 latency in the absence of additional stimuli, both in T cell models and in primary CD4⁺ T cells from people living with HIV-1 receiving cART. Targeting of CDK12/CDK13-CCNK with SR-4835 further synergized HIV-1 latency reversal and enhanced viral reactivation when co-treated with established Latency Reversal Agents. Mechanistically, CDK12/CDK13-CCNK inhibition promoted the release of P-TEFb (CDK9/CYCLIN T) from its inhibitory 7SK snRNP complex, resulting in increased recruitment of RNA polymerase II, CDK9 activation, and remodeled chromatin that overall drove productive HIV-1 transcription. Beyond HIV-1 reactivation, our findings reveal a previously unrecognized compensatory interplay between transcriptional kinases that activate gene expression, thereby rewiring cellular transcriptional programs. Together, this study identifies CDK12/CDK13-CCNK complex as a therapeutic target for HIV-1 latency reversal and provides a mechanistic rationale for improving strategies aimed at achieving an HIV cure.

  • Targeting CDK12/CDK13-CYCLIN K induces HIV-1-specific and global gene activation mediated by P-TEFb

    by Praveenkumar

    BioStudies – one package for all the data supporting a study